CEO Ulrika Kolsrud attributed the sales growth to higher volumes in the Health & Medical, Personal Care, and Professional Hygiene segments. Despite these gains, the Consumer Tissue division struggled, facing lower volumes and price pressures that the company has yet to offset through its current pricing strategy. The overall EBITA margin slipped to 13.4%, down from 13.7% in the same period last year.
In section Releases
Essity Reports Mixed Q2 2026 Results Amid Persistent Cost Inflation
Essity posted a 2.6% increase in net sales to SEK 35,061 million for the second quarter of 2026, though rising geopolitical instability and input costs weighed on margins. While organic growth reached 0.3%, the company’s EBITA excluding items affecting comparability remained nearly flat at SEK 4,685 million.
To navigate the volatile external environment, Essity is leaning into operational efficiency and digital transformation. The company has integrated AI-driven solutions across its value chain, including a new procurement tool designed to optimize data quality and reduce development lead times. Simultaneously, management continues to execute a SEK 3 billion share buyback program initiated in May, signaling confidence in the firm’s long-term value creation. Looking ahead, leadership expects the benefits of a recent organizational restructuring to materialize in the second half of the year, provided that cost-saving programs successfully mitigate ongoing transportation and raw material inflation.
Comments (0)
No comments yet. Be the first!